The WMIC produces and contributes to a range of medicines-related publications for healthcare professionals and members of the public.
COVID-19 Vaccine Advice
On 1 September 2021 the Joint Committee on Vaccination and Immunisation (JCVI) advised that a third primary dose of COVID-19 vaccine be offered to individuals aged 12 years and over with severe immunosuppression in proximity of their first or second primary COVID-19 vaccine doses. Here the WMIC provide a list of medicines that corresponds to the JAK inhibitors and other biologic immune modulators mentioned in the JCVI advice and suggest appropriate timing of a third primary dose of COVID‑19 vaccine. [updated 23 September 2021]
National COVID-19 treatment Patient Group Directions (PGDs)
These national COVID-19 treatment PGD templates are for adaptation by local health boards.
The national COVID-19 treatment PGD for oral antivirals is being run centrally for the whole of Wales within Cardiff and Vale University Health Board. A copy of the PGD is provided for information.
UKMi Medicines Q&As
Medicines Q&As are produced by UKMi pharmacists throughout the UK, and provide evidence-based, and quality controlled answers to common or unusual enquiries made to Medicines Information services.
UKMi Q&As that have been produced by and are maintained by the WMIC (the specialist UKMI centre for porphyria and complementary medicine) are listed below. These and all current UKMi Q&As are available on the Specialist Pharmacy Services website.
Note: Malathion (Derbac M) is among the suggested treatments in the above bulletin, but is currently unavailable. Alternative treatments are dimeticone and wet combing (see bulletin for details).
Cardiff & Vale UHB prescribing resources
Good Prescribing Guide and INFORM Formulary
The Guide is intended to supplement the British National Formulary and Cardiff and Vale INFORM Formulary and to provide information on local practices within the University Health Board. The guidelines are intended for adult secondary care practice. The Department of Child Health in Cardiff and Vale University Health Board produce Clinical Guidelines for use in paediatrics.
Good practice guides
The following article was adapted from a review commissioned and written by the WMIC for the Neonatal and Paediatric Pharmacists Group:
McArtney R, Bailey A, Champion H. What is a ketogenic diet and how does it affect the use of medicines? Arch Dis Child Educ Pract Ed. 2017; 102:194-9.
In conjunction with the Department of Biochemistry and Immunology, University Hospital of Wales, WMIC has published two articles on safe prescribing in the acute porphyrias:
Lockett CD and Badminton MN. Safe prescribing in the autosomal dominant acute porphyrias: a practical approach: Part I. Adverse Drug Reaction Bulletin. August 2015; No. 293: pp. 1131 – 1134
Lockett CD and Badminton MN. Safe prescribing in the autosomal dominant acute porphyrias: a practical approach: Part II. Adverse Drug Reaction Bulletin. October 2015; No. 294: pp. 1135 – 1138